2. Academic Validation
  3. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma

Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma

  • Eur J Endocrinol. 2014 Sep;171(3):R111-22. doi: 10.1530/EJE-14-0113.
Eric Baudin 1,  Mouhammed Amir Habra 2,  Frederic Deschamps 2,  Gilbert Cote 2,  Frederic Dumont 2,  Maria Cabanillas 2,  J Arfi-Roufe 2,  A Berdelou 2,  Bryan Moon 2,  Abir Al Ghuzlan 2,  Shreyaskumar Patel 2,  Sophie Leboulleux 2,  Camilo Jimenez 1
Affiliations

Affiliations

  • 1 Département de Médecine Nucléaire et de Cancérologie EndocrinienneRadiologie Interventionnelle, Chirurgie, Imagerie, Institut Gustave Roussy, Université Paris Sud, 114 Rue Edouard Vaillant 94805 villejuif Cedex, Paris, France andDepartment of Endocrine Neoplasia and Hormone DisordersUnit 1461, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, Texas 77030, USA [email protected] [email protected].
  • 2 Département de Médecine Nucléaire et de Cancérologie EndocrinienneRadiologie Interventionnelle, Chirurgie, Imagerie, Institut Gustave Roussy, Université Paris Sud, 114 Rue Edouard Vaillant 94805 villejuif Cedex, Paris, France andDepartment of Endocrine Neoplasia and Hormone DisordersUnit 1461, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, Texas 77030, USA.
PMID: 24891137 DOI: 10.1530/EJE-14-0113
Abstract

Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicians with three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large Cancer referral centers with multidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.

Figures